VivoSeq
Other

Romiplostim N01

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Romiplostim N01 is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Not yet recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Not yet recruiting·SShandong University·Phase 3·NCT06440824·60 enrolled
Romiplostim N01 for Platelet Recovery After Haploidentical HSCT
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT07321626·130 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)